Kewaunee Scientific Q3: Revenue $69.4M Q3, YTD $210.6M; EPS $0.23 (Q3), $2.09 YTD

Kewaunee Scientific reported third-quarter revenue of $69.4 million and year-to-date sales of $210.6 million, with diluted earnings of $0.23 per share for the quarter and $2.09 per share year-to-date. The company noted that year-to-date sales were boosted by the November 1, 2024 acquisition of Nu Aire, which contributed materially to revenue and product breadth. Management cited a tax discrete benefit and foreign tax rate mix as drivers of the reported effective tax rate impacting net earnings. Financial Highlights Net sales: $69.4 million (Q3 FY2026); $210.6 million (YTD), up from prior year YTD $163.3 million — growth driven by Nu Aire acquisition.Gross profit: $18.5 million (Q3); $59.2 million (YTD).Gross margin: 26.7% (Q3); 28.1% (YTD).Operating profit: $2.582 million (Q3); $11.499 million (YTD). Operating expenses represented 23.0% of sales (Q3) and 22.6% of sales (YTD).Net earnings: $1.076 million (Q3); $6.773 million (YTD). Net earnings attributable to Kewaunee: $0.692 million (Q3); $6.230 million (YTD).Diluted earnings per share: $0.23 per share (Q3); $2.09 per share (YTD). Commentary notes a tax discrete benefit and foreign tax rate mix affected the effective tax rate. Business Highlights Revenue growth and acquisition integration: Domestic nine-month sales increased approximately 29.6% year-to-date; overall nine-month sales rose to $210.6 million largely due to integration of Nu Aire.Product and brand expansion: The Nu Aire acquisition broadened Kewaunee’s product portfolio into containment, incubators, and freezers, enhancing end-user offerings across laboratories and related markets.Geographic expansion: International sales increased about 27% year-to-date, with notable billings growth in India, expanding the company’s geographic reach.Operational milestone: Completed the Nu Aire acquisition on November 1, 2024; integration of Nu Aire sales is contributing to improved gross margins and business diversification.Demand environment and outlook: Construction-related demand remains seasonally volatile; Nu Aire product lines have helped offset softness in construction-linked orders and support the company’s growth strategy going forward.Original SEC Filing: KEWAUNEE SCIENTIFIC CORP /DE/ [ KEQU ] - 10-Q - Mar. 13, 2026DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.